Form 4: Apogee CFO Sells Shares Under Pre-Arranged Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock on February 2, 2026, under a Rule 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported the sale of common stock.
• A total of 2,000 shares were sold on February 2, 2026, across three separate transactions.
• The sales were executed at weighted average prices of $65.21, $66.15, and $66.89 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
• Following these transactions, Jane Henderson beneficially owns 183,371 shares of Apogee Therapeutics common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it is an insider sale, the execution under a 10b5-1 plan indicates a pre-planned, non-discretionary transaction, which typically reduces negative sentiment associated with insider selling.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.

Negatives

• An officer of the company sold shares, which can sometimes be interpreted as a lack of confidence, though this is mitigated by the pre-arranged 10b5-1 plan.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These plans allow insiders to sell shares at predetermined times or prices to avoid accusations of trading on material non-public information, providing transparency to the market.

Related Party Transactions

• The reported transactions involve the sale of common stock by Jane Henderson, the Chief Financial Officer of Apogee Therapeutics, Inc., making it an insider transaction.

Stakeholder Impact

• Shareholders may view the sale by a key executive with slight caution, although the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Financial Officer, Jane Henderson